Survanta Intratracheal suspension

Resp distress syndrome (RDS) in premature infants.

Prevention in premature infant <1250 g birthwt or w/ evidence of surfactant deficiency Preferably w/in 15 mins of birth. Rescue Preferably by 8 hr of age. 4 mL/kg birth wt(100 mg of phospholipids/kg birth wt) intratracheally up to 4 doses in 1st 48 hr. Doses should not be given more frequently than 6 hrly. To be administered as soon as possible.

None known.

Infants <600 g birth wt. For intratracheal use only.

Not Classi

Transient bradycardia. O2 desaturation, endotracheal tube reflux & blockage, pallor, vasoconstriction, hypotension, HTN, hypocarbia, hypercarbia & apnea.

Natural bovine pulmonary surfactant; replaces deficient endogenous lung surfactant in neonates with respiratory distress syndrome. Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between alveolar surfaces and air.

Survanta 25mg/ml Intratracheal suspension manufactured by Marketed By Unimed & Unihealth Manufacturers Ltd (Abbott Pharma Product). Its generic name is Phospholipids.